iX Biopharma (S$0.235, unchanged) announced that its has obtained export listing status for Xativa, its CBD (cannabidiol) sublingual wafer.

Xativa10.20Xativa’s inclusion in the Australian Register of Therapeutic Goods (“ARTG”) list of drugs approved for export paves the way for the Company to expand its customer base beyond Australia in line with its plans to build itself into a global medicinal cannabis provider.

Available in 12.5mg and 25mg doses, Xativa is the world’s first sublingual medicinal cannabis wafer developed using iX Biopharma’s patented WaferiX sublingual delivery technology.

The export listing on the ARTG demonstrates that the product is compliant with strict standards that apply to products supplied domestically in Australia.


Globally, the growing understanding of cannabis’ unique medicinal properties has driven the transformation of aƫ tudes towards the drug.

Notably, key markets such as the US, Australia, Canada, Europe, New Zealand have rapidly announced their legalisation of cannabis over the past four years.

The transition to cannabis legalisation is set to gain momentum and support the interest in and demand for medicinal cannabis.

Leveraging the export listing approval, the Company will commence supply of Xativa to Brazil, where it is collaborating with its partners to distribute and market the product to doctors and patients.

The market value for medicinal cannabis is forecast to surge from US$41.5 million in 2021 to approximately US$103.5 million by 2024.

EvanTan7.19 “Obtaining export listing for Xativa is a significant milestone. It brings us closer to realizing our ambition of becoming a medicinal cannabis supplier to global markets. This positive development follows the timely expansion of our wafer production capacity, which will support our entry into the Brazil and other international markets.

“We expect to benefit from the sustained and dynamic growth in Brazil and are confident that this move will position us competitively to expand our footprint in markets beyond Australia.”

-- Eva Tan, Chief Commercial Officer of iX Biopharma


Apart from Brazil, the Company is also pursuing partnerships with other cannabis and pharmaceutical companies, as well as wholesale and retail distributors in other markets.

The Company currently supplies Xativa to patients with medical prescriptions in Australia via the Special Access Scheme and Authorised Prescriber Scheme.

At $0.235, market cap is $164mln and P/B is 9.9x.

The Group was loss-making in FY20 and did not pay any dividends.

According to Bloomberg, the average of the various analysts’ target prices on the stock is $0.44, representing an upside potential of 83%.


Share Prices

Counter NameLastChange
AEM Holdings3.7300.080
Avi-Tech Electronics0.275-0.015
Best World1.790-0.010
Broadway Ind0.1190.002
China Sunsine0.410-
DISA0.003-
Food Empire0.6500.030
Fortress Minerals0.345-
Geo Energy Res0.3550.005
Golden Energy0.7750.005
GSS Energy0.047-
InnoTek0.4750.025
ISDN Holdings0.4050.010
ISOTeam0.095-
IX Biopharma0.127-
Jiutian Chemical0.0760.001
KSH Holdings0.355-
Leader Env0.053-0.007
Medtecs Intl0.147-0.001
Meta Health0.0250.001
Nordic Group0.475-
Oxley Holdings0.1450.001
REX International0.2350.005
Riverstone0.6250.025
Sinostar PEC0.191-
Southern Alliance Mining0.405-
Straco Corp.0.405-
Sunpower Group0.255-
The Trendlines0.0940.001
Totm Technologies0.110-0.004
UG Healthcare0.1990.001
Uni-Asia Group0.8150.015
Wilmar Intl4.0900.030
Yangzijiang Shipbldg1.390-0.020

NextInsight RSS

rss_2 NextInsight - Latest News

Online Now

We have 396 guests and no members online